Document:

Exhibit 10.01

 

CONSULTING
AGREEMENT

 

This
CONSULTING Agreement (this “Agreement”),
entered into this 5th day of February, 2019 (the “Effective Date”), sets forth the arrangement between David
Lenigas, an individual residing at Apt 012, Le Cimabue, 16 Quai Jean-Charles Rey, Fontvieille, Monaco 98000 (“Consultant”),
and Generation Alpha, Inc., a Nevada corporation with its principal place of business located at 853 Sandhill Avenue, Carson,
California 90746 (the “Company”), with respect to compensation to which Consultant may become entitled under
the terms and conditions set forth in this Agreement.

 

W
I T N E S S E T H:

 

WHEREAS,
upon the Effective Date of this Agreement, the Consultant is joining the board of directors of the Company; and

 

WHEREAS,
Company desires to obtain services from the Consultant as an independent contractor in connection with its business and operations,
and Consultant desires to provide such services, upon the terms and conditions set forth in this Agreement.

 

NOW,
THEREFORE, in consideration of the premises, the mutual covenants of the parties herein contained and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged by each of the parties hereto, it is agreed as follows:

 

1.
Consulting Arrangement. The Company hereby contracts for the services of Consultant and Consultant agrees to perform such
duties and responsibilities and to render advice and consulting as may be requested by the Company from time to time during the
term of this consulting arrangement in connection with the Company’s business. Without limiting the generality of the foregoing,
Consultant will assist the Company with marketing, brand and Company promotion, investor and public relations (the “Services”).

 

All
Services provided by the Consultant hereunder shall be carried out to the best of his ability and in conformity with any oral
or written instructions of the Company. Consultant shall devote such business time and energies as required to enable Consultant
to fulfill his obligations hereunder. Consultant may not utilize any employees, consultants, sub-contractors or other persons
to perform any of the Services hereunder without the prior written consent of the Company.

 

2.
Compensation and Term; Expense Reimbursement.

 

	 	(a)	This
    Agreement shall become effective as of the Effective Date and, unless sooner terminated in accordance herewith, shall expire
    two years from the Effective Date with an option to renew on a monthly basis by the Company. The period from the Effective
    Date until such expiration or earlier termination is referred to herein as the “Consulting Period”. For
    services hereunder, the Company shall pay the Consultant $13,000 per month. In addition, the Company agrees to issue to the
    Consultant such number of restricted shares of the Company’s common stock equal to two percent (2%) of the Company’s
    then total shares of common stock issued and outstanding upon the Company’s common stock reaching a Market Capitalization
    (as hereinafter defined) of $76 million for ten (10) consecutive trading days, and for each additional $76 million Market
    Capitalization achieved for ten (10) consecutive trading days, up to a Market Capitalization of $380 million (for a total
    of 10% of equity compensation) during the Consulting Period. In addition, if the Company enters into a binding agreement for
    a Change in Control (as hereinafter defined) transaction during the Consulting Period or within six months from the end of
    the Consulting Period, where the Enterprise Value (as hereinafter defined) equals or exceeds a minimum value of $500 million
    (the “Enterprise Value Threshold”), then upon the successful closing of the Change in Control transaction,
    the Company shall pay the Consultant a sale bonus equal to five percent (5%) of the Enterprise Value (the “Sale Bonus”),
    in cash or stock, consistent with the type of consideration received in the Change in Control transaction.

 

    	 

     

    

 

	 	(b)	As
    used in this Agreement, the following terms shall have the following meanings:

 

	 	(i)	“Change
    in Control Transactions” means and includes each of the following

 

	 	(A)	a
    transaction or series of transactions (other than an offering of the Company’s common stock to the general public through
    a registration statement filed with the Securities and Exchange Commission) whereby any “person” or related “group”
    of “persons” (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as
    amended (the “Exchange Act”)) (other than the Company, any of its subsidiaries, an employee benefit plan
    maintained by the Company or any of its subsidiaries or a “person” that, prior to such transaction, directly or
    indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial
    ownership (within the meaning of Rule 13d-3 under the Exchange Act), of securities of the Company possessing fifty percent
    (50%) or more of the total combined voting power of the Company’s securities outstanding immediately after such acquisition;
    or
	 	 	 
	 	(B)	the
    consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more
    intermediaries) of (A) a merger, consolidation, reorganization, or business combination or (B) a sale or other disposition
    of all or substantially all of the Company’s assets in any single transaction or series of related transactions or (C)
    the acquisition of assets or stock of another entity, in each case other than a transaction:

 

	 	(1)	which
    results in the Company’s voting securities outstanding immediately before the transaction continuing to represent (either
    by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the
    transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the
    Company’s assets or otherwise succeeds to the business of the Company (the Company or such person, the “Successor
    Entity”)) directly or indirectly, at least sixty percent (60%) of the combined voting power of the Successor Entity’s
    outstanding voting securities immediately after the transaction, and
	 	 	 
	 	(2)	after
    which no person or group beneficially owns voting securities representing forty percent (40%) or more of the combined voting
    power of the Successor Entity; provided, however, that no person or group shall be treated for purposes of this
    clause (2) as beneficially owning forty percent (40%) or more of combined voting power of the Successor Entity solely as a
    result of the voting power held in the Company prior to the consummation of the transaction.

 

    	2

     

    

 

	 	(ii)	“Enterprise
    Value” means in the case of a Change in Control in which consideration is payable to the Company in respect of its
    assets or business, the total cash and non-cash (including, without limitation, the assumption of debt) consideration received
    by the Company, net of any fees and expenses in connection with the transaction; or in the case of a Change in Control in
    which consideration is payable to the Company’s stockholders, the total cash and non-cash (including, without limitation,
    the assumption of debt) consideration payable to the Company’s stockholders net of any fees and expenses in connection
    with the transaction. In the event that less than 100% of the stock or assets of the Company is purchased in the Change in
    Control transaction, the Enterprise Value shall be extrapolated from the percentage of the Company’s capital stock or
    assets impacted in such Change in Control transaction to determine if the Enterprise Value Threshold was met, but the Sale
    Bonus shall be calculated based on the actual consideration received by the Company or shareholders, as the case may be; and
	 	 	 
	 	(iii)	“Market
    Capitalization” means the value of the Company’s common stock, determined by multiplying (1) the total number
    of shares of common stock publicly reported as issued and outstanding by (2) the closing price of the Company’s common
    stock, provided, that, such Market Capitalization milestone must be achieved for ten (10) consecutive trading days.

 

	 	Notwithstanding
    the foregoing, a transaction shall not constitute a “Change in Control” if: (i) its sole purpose is to
    change the state or Country of the Company’s incorporation; (ii) its sole purpose is to create a holding company that
    will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before
    such transaction; (iii) it constitutes the Company’s initial public offering of its securities; or (iv) it is a transaction
    effected primarily for the purpose of financing the Company with cash (as determined by the board of directors in good faith
    and without regard to whether such transaction is effectuated by a merger, equity financing or otherwise).

 

	 	(c)	Consultant
    shall provide the Company with an executed Form W-9 (or Form W-8BEN) upon execution of this Agreement and shall not be entitled
    to receive any compensation hereunder unless and until such Form W-9 (or Form W-8BEN) is provided to the Company.
	 	 	 
	 	(d)	Notwithstanding
    anything to the contrary contained herein, either party may terminate this Agreement at any time after one year from the Effective
    Date with at least 30 days’ prior written notice to the other party. In the event that the Consultant is in breach of
    the terms and conditions of this Agreement, the Company may immediately terminate this Agreement, unless such breach may be
    remedied, in which case the Company may terminate this Agreement if such breach has not been remedied to the Company’s
    satisfaction within five (5) days of written notice to the Consultant of such breach. The monthly consulting fee shall be
    pro-rated to the date of termination.
	 	 	 
	 	(e)	Company
    shall reimburse Consultant promptly for any and all expenses reasonably incurred in connection with its performance of the
    Services. Reimbursement shall be conditioned on proper documentation in accordance with Company’s policies applicable
    to its employees generally.

 

3.
Independent Contractor Relationship. This Agreement is intended to create an independent contractor relationship between
Consultant and Company, which is described in Section 3508 of the Internal Revenue Service Code, and shall be interpreted to effectuate
such intent between the parties.

 

	 	(a)	No
    Taxes Withheld from Compensation. Company will not withhold any taxes from any compensation paid to Consultant according
    to this Agreement. It is acknowledged and agreed by the parties that Company has not, is not, and shall not be obligated to
    make, and that it is the sole responsibility of Consultant to make, in connection with compensation paid to Consultant according
    to this Agreement, all periodic filings and payments required to be made in connection with any withholding taxes, FICA taxes,
    Federal unemployment taxes, and any other federal, state or local taxes, payments or filings required to be paid, made or
    maintained.

 

    	3

     

    

 

	 	(b)	Consultant
    Controls Time and Effort. It is agreed that Company is interested only in the ultimate results of Consultant’s activities
    pursuant to this Agreement and that Consultant shall have exclusive control over the time and effort invested by Consultant
    pursuant to this Agreement and the manner and means of Consultant’s performance under this Agreement, provided, however,
    that the Consultant shall meet such project deadlines as established by the Company from time to time.
	 	 	 
	 	(c)	Independence
    from Company. The parties further agree that Consultant shall have no control or supervision over Company’s employees,
    officers, directors, representatives or affiliates. Consultant will not represent that it is an employee of Company. Consultant
    shall at all times represent himself and be construed as independent of Company. Consultant shall not, under any circumstances,
    be deemed to be a servant or employee of Company for any purpose, including for Federal tax purposes. Consultant’s relationship
    to Company is that of an independent contractor, and nothing in this Agreement shall constitute this Agreement as a joint
    venture or partnership between Consultant and the Company. Consultant shall have no authority to bind Company or any of its
    employees, officers, directors, representatives or affiliates by any promise or representation, oral or otherwise, unless
    specifically authorized in a writing bearing an authorized signature of a Company officer, director or representative.

 

4.
Confidential Information. Consultant acknowledges that, pursuant to this Agreement, it may be given access by the Company
or its affiliates to, or may become acquainted as a result of its services hereunder with, certain proprietary information, trade
secrets or both, of the Company and its affiliates (collectively, the “Confidential Information”). Consultant
acknowledges and agrees that it acquires no ownership interest in such information by reason of its disclosure to him under this
Agreement.

 

5.
Nondisclosure of Confidential Information. During and following the Consulting Period, the Consultant will hold in confidence
the Confidential Information and shall not in any manner, either directly or indirectly, use, divulge, disclose or communicate
to any person or entity any of the Confidential Information except with the specific prior written consent of the Company or except
as otherwise expressly permitted by the terms of this Agreement. Consultant expressly agrees that the Confidential Information
affects the successful and effective conduct of Company’s business and its good will and that any breach of the terms of
this Section by Consultant is a breach of this Agreement.

 

The
Consultant recognizes that, as between the Company and the Consultant, any document, record, notebook, plan, model, component,
device, or computer software or code, whether embodied in a disk or in any other form (collectively, the “Proprietary
Items”), whether or not developed by the Consultant, are the exclusive property of the Company. Upon termination of
this Agreement by either party, or upon the request of the Company during the Consulting Period, the Consultant shall return to
the Company, or destroy (and certify to such destruction in writing to the Company), all of the Proprietary Items in the Consultant’s
possession or subject to the Consultant’s control, and the Consultant shall not retain any copies, abstracts, sketches,
or other physical embodiment of any of the Proprietary Items.

 

6.
Exceptions to Nondisclosure. Notwithstanding anything to the contrary contained in this Agreement, Consultant shall not
be prohibited from disclosing to third parties, or using without the prior written consent of Company, information that (a) was,
on the date of this Agreement, generally known to the public, (b) is as of the date of this Agreement known to Consultant, as
evidenced by written records in the possession of Consultant, (c) is subsequently disclosed to Consultant by a third party who
is in lawful possession of such information and is not under an obligation of confidence, (d) is disclosed by Company to third
parties generally without restriction on use and disclosure, or (e) is required to be disclosed by law or a final order of a court
or other governmental agency or authority of competent jurisdiction, provided, however, reasonable notice prior to any disclosure
as required by applicable law or court process shall be given to Company which would allow Company sufficient time to attempt
to obtain injunctive relief in respect to such disclosure.

 

    	4

     

    

 

7.
Work for Hire; Ownership of Work Product.

 

	 	(a)
    	“Work
    Product” means all computer software, designs, ideas, discoveries, works of authorship, products, programs, procedures,
    formulae, processes, manufacturing techniques, graphic design, interfaces, inventions, improvements and ideas, conceived,
    created, developed or reduced to practice by Consultant, alone or with others, which arise out of or are created in connection
    with the Services during the Consulting Period. The Company and the Consultant understand, acknowledge and agree that all
    Work Product shall be deemed “work for hire” within the meaning of the U.S. Copyright Laws and that the Company
    shall be deemed the Author thereof and Owner of all rights therein and thereto, including without limitation the copyright
    thereof and all derivative works thereto throughout the world in all media in perpetuity.
	 	 	 
	 	(b)
    	To
    the extent any of Consultant’s Work Product is not deemed “work for hire”, Consultant hereby irrevocably
    assigns, conveys and otherwise transfers to the Company, and its respective successors and assigns, all rights, title and
    interest worldwide in and to the Work Product and all proprietary rights therein, including, without limitation, all copyrights,
    trademarks, design patents, trade secret rights, moral rights, and all contract and licensing rights, and all claims and causes
    of action of any kind with respect to any of the foregoing, whether now known or hereafter to become known.
	 	 	 
	 	(c)
    	In
    the event Consultant has any rights in and to the Work Product that cannot be assigned to the Company, Consultant hereby unconditionally
    and irrevocably waives the enforcement of all such rights, and all claims and causes of action of any kind with respect to
    any of the foregoing against the Company, its distributors and customers, whether now known or hereafter to become known and
    agrees, at the request and expense of the Company and its respective successors and assigns, to consent to and join in any
    action to enforce such rights and to procure a waiver of such rights from the holders of such rights.
	 	 	 
	 	(d)
    	In
    the event Consultant has any rights in and to the Work Product that cannot be assigned to the Company and cannot be waived,
    Consultant hereby grants to Company, and its respective successors and assigns, an exclusive, worldwide, royalty-free license
    during the term of the rights to reproduce, distribute, modify, publicly perform and publicly display, with the right to sublicense
    and assign such rights in and to the Work Product including, without limitation the right to use in any way whatsoever that
    Work Product. Consultant retains no rights to use the Work Product and agrees not to challenge the validity of the ownership
    by the Company in the Work Product.
	 	 	 
	 	(e)
    	Consultant
    agrees to assist the Company in any reasonable manner to obtain and enforce for the Company’s benefit patents, copyrights,
    and other property rights covering the Work Product in any and all countries. Consultant agrees to execute, when requested,
    patent, copyright, or similar applications and assignments to the Company, and any other lawful documents deemed necessary
    by the Company to carry out the purpose of this Agreement. Consultant further agrees that the obligations and undertaking
    stated in this Section 7(e) will continue beyond the termination of Consultant’s service to the Company.
	 	 	 
	 	(f)
    	In
    the event that the Company is unable for any reason whatsoever to secure Consultant’s signature to any lawful and necessary
    document required to apply for or execute any patent, copyright, or other applications with respect to any Work Product (including
    improvements, renewals, extensions, continuations, divisions or continuations in part thereof), Consultant hereby irrevocably
    designates and appoints the Company and its duly authorized officers and agents as his or her agents and attorneys-in-fact
    to act for and in his or her behalf and instead of Consultant, to execute and file any such application and to do all other
    lawfully permitted acts to further the prosecution and issuance of patents, copyrights or other rights therein with the same
    legal force and effect as if executed by Consultant.

 

    	5

     

    

 

8.
Representations and Warranties. Consultant represents and warrants to the Company that:

 

	 	(a)	He
    has the power, authority, and legal capacity to enter into and to perform this Agreement;
	 	 	 
	 	(b)	this
    Agreement when executed and delivered by the Consultant will be a legal, valid and binding obligation enforceable against
    the Consultant in accordance with its terms;
	 	 	 
	 	(c)	[Intentionally
    omitted]
	 	 	 
	 	(d)	unless
    covered by an appropriate agreement between any third party and the Company, the Consultant shall not engage in any activities
    or use any facilities in the course of providing the Services, which could result in the claims of ownership to any Work Product
    made by such third party;
	 	 	 
	 	(e)	neither
    the execution and delivery by the Consultant of this Agreement, nor the performance by the Consultant of the Services contemplated
    hereby, will conflict with, result in a breach of, constitute (with or without due notice or lapse of time or both) a default
    under, result in the acceleration of obligations under, create in any party the right to terminate, modify or cancel, or require
    any notice, consent or waiver under, any contract or instrument to which the Consultant is a party or by which the Consultant
    is bound (including any agreements relating to the confidential or proprietary information of a third party);
	 	 	 
	 	(f)	except
    for material specifically identified by the Consultant in a written notice to the Company and specifically acknowledged by
    the Company in writing as either (i) material in the public domain or (ii) material from other works as may be included with
    the written permission of the owners of all rights therein, the Services and the Work Product is and shall be original to
    Consultant, and no Person (other than the Company) has or shall have any rights thereto. For purposes of this Agreement, “Person”
    means any individual, partnership, corporation, limited liability company, association, joint venture, organization, trust
    or other entity;
	 	 	 
	 	(g)	no
    portion of the Work Product infringes or misappropriates or will infringe or misappropriate any Intellectual Property Rights
    of any other Person, violates or will violate any right of privacy or any property rights of any Person, or is or will be
    libelous or obscene. For purposes of this Agreement, “Intellectual Property Rights” means all United States
    and foreign letter patent, patents, patent applications, trademarks, service marks, trade names, brand names, logos and other
    trade designations (including unregistered names and marks), trademark and service mark registrations and applications, copyrights,
    copyright registrations and applications, inventions (both patentable and unpatentable), invention disclosures, protected
    formulae, formulations, processes, methods, substances, trade secrets, computer software and firmware, computer programs and
    source codes, manufacturing research and similar technical information, engineering know how, customer and supplier information,
    assembly and test data drawings, hardware and software designs, royalty rights and other similar items or proprietary rights
    therein.

 

9.
Indemnification. Consultant agrees to indemnify and hold harmless the Company, its affiliates and its and their respective
directors, officers, partners, members, managers, employees, and agents (each, an “Indemnified Party”), against
and in respect of all losses, liabilities, obligations, damages, deficiencies, actions, suits, proceedings, demands, assessments,
orders, judgments, costs and expenses (including the reasonable fees, disbursements and expenses of attorneys and consultants)
of any kind or nature whatsoever to the extent sustained, suffered or incurred by or made against any Indemnified Party, to the
extent based upon, arising out of or in connection with: (a) any breach of this Agreement, or (b) any infringement or misappropriation
of any Intellectual Property Rights in connection with the Work Product (including its use by the Company and its direct or indirect
customers or licensees).

 

    	6

     

    

 

10.
Injunctive Relief and Damages. Consultant acknowledges and agrees that the covenants and obligations of Consultant set
forth in Section 5 with respect to confidentiality relate to special, unique and extraordinary matters and that a violation of
any of the terms of such covenants and obligations will cause the Company irreparable injury for which adequate remedies are not
available at law. Therefore, Consultant agrees that the Company shall be entitled to an injunction, restraining order or such
other equitable relief (without the requirement to post bond) as a court of competent jurisdiction may deem necessary or appropriate
to restrain Consultant from committing any violation of the covenants and obligations referred to in Section 7. These injunctive
remedies are cumulative and in addition to any other rights and remedies the Company may have at law or in equity. Nothing contained
in this Section 10 shall be construed as prohibiting the Company from pursuing any other remedies available to it for any such
breach or threatened breach, including recovery of damages and an equitable accounting of all earnings, profits and other benefits
arising from such violation.

 

11.
Governing Law and Jurisdiction. The Company and the Consultant hereby irrevocably and unconditionally consent to submit
to the exclusive jurisdiction of the courts of the State of New York, New York County, and of the United States District Court
for the Southern District of New York for any lawsuits, actions or other proceedings arising out of or relating to this Agreement
and agree not to commence any such lawsuit, action or other proceeding except in such courts. The Company and the Consultant further
agree that service of any process, summons, notice or document by mail, return receipt requested, to the address of such party
set forth above shall be effective service of process for any lawsuit, action or other proceeding brought against such party in
any such court. The Company and the Consultant hereby irrevocably and unconditionally waive any objection to the laying of venue
of any lawsuit, action or other proceeding arising out of or relating to this Agreement in the courts of the State of New York,
New York County, and of the United States District Court for the Southern District of New York, and hereby further irrevocably
and unconditionally waive and agree not to plead or claim in any such court that any such lawsuit, action or other proceeding
brought in any such court has been brought in an inconvenient forum.

 

12.
Severability. If the law does not allow a provision of this Agreement to be enforced, such unenforceable provision shall
be amended to become enforceable and reflect the intent of the parties, and the rest of the provisions of this Agreement shall
remain in effect.

 

13.
Waiver. The failure of any party, in any instance, to insist upon strict enforcement of the provisions of this Agreement
shall not be construed to be a waiver or relinquishment of enforcement in the future, and the terms of this Agreement shall continue
to remain in full force and effect.

 

14.
Assignability. This Agreement shall not be assignable by either party except that the Company may assign any or all of
its rights and interests hereunder to one or more affiliates.

 

16.
Amendment. This Agreement may only be amended or modified in a writing signed by both of the parties and referring to this
Agreement.

 

17.
Entire Agreement. This Agreement constitutes the entire agreement and final understanding of the parties with respect to
the subject matter of this Agreement and supersedes and terminates all prior and/or contemporaneous understandings and/or discussions
between the parties, whether written or verbal, express or implied, relating in any way to the subject matter of this Agreement.

 

18.
Judicial Interpretation. Should any provision of this Agreement require judicial interpretation, it is agreed that a court
interpreting or construing the same shall not apply a presumption that the terms hereof shall be more strictly construed against
any party by reason of the rule of construction that a document is to be construed more strictly against the party who itself
or through its agent prepared the same, it being agreed that both parties have participated in the preparation of this Agreement.

 

19.
Survival. Consultant agrees that the provisions of Sections 5 – 19 shall survive expiration or earlier termination
of this Agreement for any reasons, whether voluntary or involuntary, with or without cause, and shall remain in full force and
effect thereafter.

 

20.
Execution in Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be
considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered
to the other party. In the event that any signature is delivered by facsimile transmission or by an e-mail which contains a portable
document format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of
the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were
an original thereof.

 

[signature
page follows]

 

    	7

     

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first written above.

 

	 	GENERATION
    ALPHA, INC.
	 	 	 
	 	By:	/s/
    TIFFANY DAVIS
	 	Name:
    	Tiffany
    Davis
	 	Title:
    	Chief
    Operating Officer
	 	 	 
	 	 	/s/
    DAVID LENIGAS
	 	 	David
    Lenigas

 

    	8Exhibit 10.11

 

REGISTRATION RIGHTS
AGREEMENT

 

THIS
REGISTRATION RIGHTS AGREEMENT (as may be amended or modified from time to time, this “Agreement”) is
made and entered into as of  February 8, 2019 by and among Avenue Therapeutics, Inc., a Delaware corporation (the
“Company”), and InvaGen Pharmaceuticals Inc., a New York corporation (“Buyer”).

 

WHEREAS, the
Company and Buyer entered into that certain Stock Purchase and Merger Agreement, dated as of November 12, 2018 (the “SPMA”);
and

 

WHEREAS, in
connection with the execution and delivery of the SPMA and the consummation of the transactions contemplated thereby, the Company
has agreed to grant Buyer certain registration rights as set forth below.

 

NOW, THEREFORE,
in consideration of the mutual promises and covenants herein contained, and other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the parties agree as follows:

 

Section 1. Definitions

 

Capitalized terms used
but not defined in this Agreement shall have the respective meanings ascribed to them in the SPMA.   

 

“Agent”
means the principal placement agent on an agented placement of Registrable Securities.

 

“Automatic
Shelf Registration Statement” shall have the meaning specified in Rule 405 under the Securities Act.

 

“Prospectus”
means the prospectus or prospectuses included in any Registration Statement (including any “free writing prospectus”
(as defined in Rule 405 of the Securities Act) and any prospectus subject to completion and a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated
under the Securities Act), as amended or supplemented by any prospectus supplement with respect to the terms of the offering of
any portion of the Registrable Securities covered by such Registration Statement and by all other amendments and supplements to
the prospectus, including post-effective amendments and all material incorporated by reference or deemed to be incorporated by
reference in such prospectus or prospectuses.

 

“Registrable
Securities” means the Common Shares and any Securities into which the Common Shares may be converted or exchanged pursuant
to any merger, consolidation, sale of all or any part of its assets, corporate conversion or other extraordinary transaction of
the Company, held by the Buyer (whether now held or hereafter acquired, and including any such Securities received by the Buyer
upon the conversion or exchange of, or pursuant to such a transaction with respect to, other Securities held by the Buyer). As
to any particular Registrable Securities, such Securities shall cease to be Registrable Securities on the earliest to occur of:
(a) the date on which a Registration Statement with respect to the sale of such Registrable Securities shall have become effective
under the Securities Act and such Registrable Securities shall have been sold, transferred or disposed of in accordance with such
Registration Statement; (b) the date on which such Registrable Securities shall have ceased to be outstanding; (c) any date on
which Company counsel delivers a written opinion of counsel, which shall be in a form reasonably satisfactory to Buyer’s
counsel, to the effect that such Buyer’s Registrable Securities are eligible for sale without registration pursuant to Rule
144 (or any successor provision) under the Securities Act and without volume limitations or other restrictions on transfer thereunder;
or (d) the date on which such Registrable Securities have been sold to a third party and all transfer restrictions and restrictive
legends with respect to such Registrable Securities are removed upon the consummation of such sale.

 

     

     

    

 

“Registration
Statement” means any registration statement filed by the Company with the SEC in compliance with the Securities Act for
a public offering and sale of the Common Shares or other securities of the Company, including the Prospectus, amendments and supplements
to such Registration Statement, including pre- and post-effective amendments, all exhibits and all materials incorporated by reference
or deemed to be incorporated by reference in such Registration Statement (other than a registration statement (i) on Form S-4 or
Form S-8 or any successor form to Form S-4 or Form S-8 or in connection with any employee or director welfare, benefit or compensation
plan, (ii) covering only Securities proposed to be issued in exchange for Securities or assets of another entity, (iii) in connection
with an exchange offer or an offering of Securities exclusively to existing Security holders of the Company or its subsidiaries,
(iv) relating to a transaction pursuant to Rule 145 of the Securities Act, (v) for an offering of debt that is convertible into
equity Securities of the Company, or (vi) solely for a dividend reinvestment plan).

 

“Securities”
means capital stock, limited partnership interests, limited liability company interests, beneficial interests, warrants, options,
notes, bonds, debentures, and other securities, equity interests, ownership interests and similar obligations of every kind and
nature of any Person.

 

“Shelf Registration
Statement” means a Registration Statement on Form S-3 or another appropriate form for an offering to be made on a delayed
or continuous basis pursuant to Rule 415 under the Securities Act.

 

“Transfer”
means and includes the act of selling, giving, transferring, creating a trust (voting or otherwise), assigning or otherwise disposing
of (other than pledging, hypothecating or otherwise transferring as security or any transfer upon any merger or consolidation)
(and correlative words shall have correlative meanings); provided, however, that any transfer or other disposition upon
foreclosure or other exercise of remedies of a secured creditor after an event of default under or with respect to a pledge, hypothecation
or other transfer as security shall constitute a Transfer.

 

“Underwriters’
Representative” means the managing underwriter, or in the case of a co-managed underwriting, the managing underwriter
designated as the Underwriters’ Representative by the co-managers.

 

“WKSI”
shall mean a well-known seasoned issuer, as defined in Rule 405 under the Securities Act.

 

    2 

     

    

 

Section 2. Registration Rights

 

(a)      Shelf Registrations.
At any time and from time to time on or after the First Stage Closing, the Buyer may deliver to the Company a written notice (a
“Shelf Registration Notice”) requiring the Company to prepare and file with the SEC a Shelf Registration Statement
with respect to resales of some or all Registrable Securities by the Buyer. As promptly as practicable after receiving the Shelf
Registration Notice, but in no event more than 45 days following receipt of such notice, the Company shall file with the SEC a
Shelf Registration Statement covering all requested Registrable Securities and, unless such Shelf Registration Statement shall
become automatically effective, the Company shall use commercially reasonable efforts to cause the Shelf Registration Statement
to become or be declared effective by the SEC for all of the Registrable Securities covered thereby as promptly as practicable
following delivery of the Shelf Registration Notice (if it is not an automatically effective Shelf Registration Statement). To
the extent the Company is a WKSI at the time that the Shelf Registration Statement is to be filed, the Company shall file an automatic
Shelf Registration Statement which covers such Registrable Securities. The Company agrees to use commercially reasonable efforts
to keep the Shelf Registration Statement (or a successor Registration Statement filed with respect to the Registrable Securities)
continuously effective (including by filing a new Shelf Registration Statement if the initial Shelf Registration Statement expires)
in order to permit the Prospectus forming a part thereof to be lawfully delivered and the Shelf Registration Statement useable
for resale of the Registrable Securities, so long as there are any Registrable Securities outstanding (the “Shelf Effectiveness
Period”).

 

(b)     Shelf
Offerings. In the event of the termination of the SPMA following the First Stage Closing, and at any time thereafter during
the Shelf Effectiveness Period, the Buyer may deliver to the Company a written notice (“Shelf Offering Notice”)
requiring the Company to facilitate a “takedown” of Registrable Securities off of the Shelf Registration Statement
(“Shelf Offering”). As promptly as reasonably practicable upon receipt of the Shelf Offering Notice, the Company
shall use commercially reasonable efforts to facilitate such a “takedown” by amending or supplementing the Prospectus
related to the Shelf Registration Statement as may be reasonably requested by the Buyer and taking other actions contemplated
by Section 3.1 that may be applicable to such Shelf Offering.

 

(c)      Non-Shelf
Demand Registration. At any time and from time to time, if the Company has not effected or is not diligently pursuing a Shelf
Registration Statement pursuant to Section 2(a) or the Company is not eligible to file a Shelf Registration Statement or
the Shelf Registration Statement filed pursuant to Section 2(a) shall cease to be effective, the Buyer may deliver to the
Company a written notice (a “Non-Shelf Demand Registration Notice”) informing the Company that the Buyer requires
the Company to register for resale some or all of such Buyer’s Registrable Securities (a “Non-Shelf Demand Registration”).
Upon receipt of the Non-Shelf Demand Registration Notice, the Company will use commercially reasonable efforts to file with the
SEC as promptly as practicable after receiving the Non-Shelf Demand Registration Notice, but in no event more than 45 days following
receipt of such notice, a Registration Statement covering all requested Registrable Securities (the “Non-Shelf Demand
Registration Statement”), and agrees to use commercially reasonable efforts to cause the Non-Shelf Demand Registration
Statement to be declared effective by the SEC as soon as reasonably practicable following the filing thereof. The Company agrees
to use reasonable efforts to keep any Non-Shelf Demand Registration Statement continuously effective (including the preparation
and filing of any amendments and supplements necessary for that purpose) for a period of not less than 120 days (“Minimum
Effective Period”).

 

    3 

     

    

 

(d)      All
offers and sales by the Buyer under a Non-Shelf Demand Registration Statement shall be completed within the period during which
such Non-Shelf Demand Registration Statement remains effective and not the subject of any stop order, injunction or other order
of the SEC. Upon notice that such Non-Shelf Demand Registration Statement is no longer effective, the Buyer will not offer or sell
the Registrable Securities under the Non-Shelf Demand Registration Statement.

 

(e)      Neither
the Company nor any stockholder of the Company (other than the Buyer) may include securities in any offering requested under Section
2 of this Agreement.

 

(f)      Underwritten
Offerings. If any registration or offering pursuant to this Section 2 involves an underwritten offering (whether on
a “firm,” “best efforts” or “all reasonable efforts” basis or otherwise), or an agented offering,
the Buyer shall have the right to select the counsel representing the Buyer in such registration or offering, the underwriter
or underwriters and manager or managers to administer such underwritten offering or the placement agent or agents for such agented
offering.

 

Section 3. Additional Obligations of
the Company and the Buyer

 

3.1 Obligations
of the Company. When the Company is required to effect the registration of any Registrable Securities or facilitate or effect
any offering pursuant to Section 2 of this Agreement, the Company shall:

 

(a)      use
commercially reasonable efforts to (i) register or qualify the Registrable Securities within a reasonable time after the applicable
Registration Statement is declared effective by the SEC under all applicable state securities or “blue sky” laws of
such jurisdictions as the Buyer may reasonably request in writing, (ii) keep each such registration or qualification effective
during the period such Registration Statement is required to be kept effective pursuant to this Agreement, (iii) cooperate with
the Buyer and the underwriters or Agents, if any, and their respective counsel in connection with any filings required to be made
with FINRA or other applicable regulatory authorities, and (iv) to do any and all other similar acts and things that may be reasonably
necessary or advisable to enable the Buyer to consummate the disposition of the Registrable Securities in each such jurisdiction;
provided, however, that the Company shall not be required to (A) qualify generally to do business in any jurisdiction as
a foreign corporation or to register as a broker or dealer in any jurisdiction where it would not otherwise be required to so qualify
or register but for this Agreement, (B) take any action that would cause it to become subject to any taxation in any jurisdiction
where it would not otherwise be subject to such taxation or (C) take any action that would subject it to the general service of
process in any jurisdiction where it is not then so subject;

 

(b)      promptly
notify the Buyer of the receipt, and provide copies to the Buyer, of any comments or other correspondence from staff of the SEC
with respect to any Registration Statement, and promptly respond to such comments (subject to Section 3.1(n)) and provide
copies of such responses to the Buyer;

 

(c)      as
promptly as practicable, prepare and file with the SEC, if necessary, such amendments and supplements to the Registration Statement
and the Prospectus used in connection with such Registration Statement or any document incorporated therein by reference or file
any other required document as may be necessary to cause or maintain the effectiveness of such Registration Statement for so long
as such Registration Statement is required to be kept effective and to comply with the provisions of the Securities Act and the
rules thereunder with respect to the disposition of all securities covered by such Registration Statement and the instructions
applicable to the registration form used by the Company;

 

    4 

     

    

 

(d)      in
the event that any Registrable Securities included in a Registration Statement subject to, or required by, this Agreement remain
unsold at the end of the period during which the Company is obligated to maintain the effectiveness of such Registration Statement,
file a post-effective amendment to the Registration Statement for the purpose of removing such securities from registered status;

 

(e)      furnish,
without charge, to the Buyer such number of copies of the Registration Statement, each amendment and supplement thereto (in each
case including all exhibits, but excluding any documents to be incorporated by reference therein that are publicly available on
the SEC’s Electronic Data Gathering, Analysis and Retrieval system (“EDGAR”)), and the Prospectus included
in such Registration Statement (including each preliminary Prospectus) in conformity with the requirements of the Securities Act
as the Buyer or any underwriter or Agent may reasonably request for use in and in order to facilitate the public sale or other
disposition of the Registrable Securities owned by the Buyer;

 

(f)      if
a disposition of Registrable Securities takes the form of an underwritten or agented offering, any “bought deal” or
block trade, promptly enter into customary agreements (including, in the case of an underwritten offering, underwriting agreements
in customary form, and including provisions with respect to indemnification and contribution in customary form and consistent with
the provisions relating to indemnification and contribution contained herein) and promptly take all other customary actions at
such times as customarily occur in similar registered offerings in order to facilitate the disposition of such Registrable Securities
and in connection therewith, including:

 

(i)          make
such representations and warranties to the Buyer and the underwriters, if any, in form, substance and scope as are customarily
made by issuers in similar underwritten offerings;

 

(ii)         obtain
opinions of counsel to the Company and updates thereof (which counsel and opinions (in form, scope and substance) shall be reasonably
satisfactory to the Buyer and the Underwriter’s Representative or Agent, if any) addressed to the Buyer and the underwriters,
if any, covering the matters customarily covered in opinions requested in sales of securities or underwritten offerings and such
other matters as may be reasonably requested by the Buyer and the lead managing underwriter, and the Company shall furnish to the
Buyer a signed counterpart of any such legal opinion;

 

(iii)        obtain
“cold comfort” letters and updates thereof from the Company’s independent certified public accountants addressed
to the Buyer, if permissible, and the underwriters, if any, which letters shall be customary in form and shall cover matters of
the type customarily covered in “cold comfort” letters to underwriters in connection with primary underwritten offerings,
and the Company shall furnish to the Buyer a signed counterpart of any such comfort letter; and

 

(iv)        use
commercially reasonable efforts to obtain executed lock-up agreements from the officers and directors of the Company and from the
holders of more than 5% of the Company’s equity securities (who are, or whose associated persons are, bound by the Company’s
insider trading policy), if requested by the underwriters for such time periods as the underwriters may reasonably request.

 

    5 

     

    

 

(g)     promptly
notify the Buyer: (i) when the Registration Statement, any pre-effective amendment, the Prospectus or any prospectus supplement
related thereto or post-effective amendment to the Registration Statement has been filed, and, with respect to the Registration
Statement or any post-effective amendment, when the same has become effective, (ii) of the issuance by the SEC of any stop order
suspending the effectiveness of the Registration Statement or the initiation or threat of any proceedings for that purpose, and
(iii) of the receipt by the Company of any notification with respect to the suspension of the qualification of any Registrable
Securities for sale under the securities or “blue sky” laws of any jurisdiction or the initiation of any proceeding
for such purpose;

 

(h)     use
commercially reasonable efforts to prevent the issuance of any order suspending the effectiveness of a Registration Statement
or suspending the qualification or exemption from qualification under state securities or “blue sky” laws, and, if
any such order suspending the effectiveness of a Registration Statement or suspending the qualification or exemption from qualification
under state securities or “blue sky” laws is issued, shall promptly use commercially reasonable efforts to obtain
the withdrawal of such order at the earliest possible moment (and shall provide the Buyer with prompt notice thereof);

 

(i)      after
the filing of a Registration Statement and thereafter until the expiration of the period during which the Company is required to
maintain the effectiveness of the applicable Registration Statement as set forth in the applicable Sections above, promptly notify
the Buyer: (i) of the existence of any fact of which the Company is aware or the happening of any event which has resulted in (A)
the Registration Statement, as then in effect, containing an untrue statement of a material fact or omitting to state a material
fact required to be stated therein or necessary to make any statements therein not misleading, (B) the Prospectus included in such
Registration Statement containing an untrue statement of a material fact or omitting to state a material fact necessary to make
any statements therein, in the light of the circumstances under which they were made, not misleading or (C) the representations
and warranties of or relating to the Company contained in any agreement for the sale of any Registrable Securities under a Registration
Statement ceasing to be true and correct in any material respect and (ii) of the Company’s reasonable determination that
a post-effective amendment to the Registration Statement would be appropriate or required or that there exist circumstances not
yet disclosed to the public which make further sales under such Registration Statement inadvisable pending such disclosure and
post-effective amendment; and, if the notification relates to any event described in either of clauses (i) or (ii) of this Section
3.1(i), at the request of the Buyer, the Company shall promptly prepare and file with the SEC a post-effective amendment to
the Registration Statement or a supplement to the Prospectus and furnish to the Buyer a reasonable number of copies of such post-effective
amendment or supplement or file any other required document so that (x) such Registration Statement shall not contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading and (y) such Prospectus shall not include an untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading;

 

    6 

     

    

 

(j)      in
the event that the Common Shares are listed on a national securities exchange, use commercially reasonable efforts to cause all
such Registrable Securities to be listed, and to maintain the listing of such Registrable Securities, on the national securities
exchange on which the Common Shares are then listed and cause to be satisfied all requirements and conditions of such securities
exchange to the listing or quoting of such securities that are reasonably within the control of the Company including registering
the applicable class of Registrable Securities under the Exchange Act, if appropriate, and using commercially reasonable efforts
to cause such registration to become effective pursuant to the rules of the SEC in accordance with the terms hereof;

 

(k)      if
requested by the Buyer during the offering of Registrable Securities, incorporate in a prospectus supplement or post-effective
amendment such information concerning the Buyer or the intended method of distribution as the Buyer reasonably requests to be included
therein and is reasonably necessary to permit the sale of the Registrable Securities pursuant to the Registration Statement, including
information with respect to the number of Registrable Securities being sold, the purchase price being paid therefor and any other
material terms of the offering;

 

(l)      make
available to its stockholders, as soon as practicable but no later than 90 days following the end of the 12-month period beginning
with the first month of the Company’s first fiscal quarter commencing after the effective date of each Registration Statement
filed pursuant to this Agreement an earnings statement satisfying the provisions of Section 11(a) of the Securities Act
and Rule 158 thereunder;

 

(m)     make the Company’s executive officers available for customary presentations to investors to discuss the affairs of the Company
at times that may be mutually and reasonably agreed upon (including to the extent customary, senior management participation in
due diligence calls with the underwriters (or Agent) and their counsel and, in the case of any marketed underwritten offering,
participation in any road show as reasonably requested by the lead managing underwriters for such offering), and provide the Buyer,
the underwriters and their respective counsel, accountants and other advisors (the “Inspectors”) reasonable
access to its books and records as shall be reasonably requested in order to conduct a reasonable due diligence investigation within
the meaning of the Securities Act with respect to any applicable Registration Statement; provided, that such Inspectors
agree to keep such information confidential (subject to customary exceptions) unless the disclosure of such information is necessary
to avoid or correct a misstatement or omission in such Registration Statement;

 

(n)      in
connection with the preparation and filing of any Registration Statement, Prospectus, any amendments or supplements thereto, and
any other written communications with the SEC with respect thereto, (i) give the Buyer, the underwriters or Agent (if applicable)
and their respective counsels the opportunity to review and provide comments on such Registration Statement, each Prospectus included
therein or filed with the SEC, each amendment thereof or supplement thereto, and any other written communications with the SEC
with respect thereto, (ii) fairly and in good faith consider such comments in any such documents prior to the filing thereof as
the counsel to the Buyer or underwriters may reasonably request, and (iii) make available such of the Company’s representatives
as shall be reasonably requested by the Buyer or any underwriter for discussion of such documents;

 

(o)      provide
and cause to be maintained a transfer agent and registrar for all Registrable Securities covered by such Registration Statement
from and after a date not later than the effective date of such Registration Statement;

 

 

    7 

     

    

 

(p)      cooperate
with the Buyer to facilitate the timely delivery, preparation and delivery of certificates (or evidence of direct registration),
with requisite CUSIP numbers, representing Registrable Securities to be sold;

 

(q)      to
the extent the Company is a WKSI during the period in which this Agreement is in effect, use commercially reasonable efforts to
take such actions as under its control to remain a WKSI and not become an ineligible issuer during the period when any Registration
Statement remains in effect; and

 

(r)      take
such other actions as are reasonably required in order to expedite or facilitate the disposition of Registrable Securities included
in each such registration.

 

Section 4. Indemnification; Contribution

 

4.1 Indemnification
by the Company. The Company agrees to indemnify and hold harmless the Buyer and each Person, if any, who controls the Buyer
within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, and any of their partners, members, officers,
directors, employees, agents, advisors or representatives, as follows:

 

(a)      against
any and all loss, liability, claim, damage, action, cost, judgment and expense whatsoever (including reasonable fees, expenses
and disbursements of attorneys and other professionals), as incurred, arising out of or based upon: (i) any untrue statement or
alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto) pursuant to which
the Registrable Securities were registered under the Securities Act, including all documents incorporated therein by reference,
or in any Prospectus (or any amendment or supplement thereto), including all documents incorporated therein by reference, (ii)
the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading, or (iii) any other violation or alleged
violation by the Company (or any of its Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule
or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law, relating to a Registration Statement,
Prospectus or amendment or supplement thereto filed in accordance with this Agreement.

 

(b)      against
any and all loss, liability, claim, damage, action, cost, judgment and expense whatsoever (including reasonable fees, expenses
and disbursements of attorneys and other professionals), as incurred, to the extent of the aggregate amount paid in settlement
of any litigation, or investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim
whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; and

 

(c)      against
any and all cost or expense whatsoever, as incurred (including reasonable fees, expenses and disbursements of attorneys and other
professionals), reasonably incurred in investigating, preparing, defending against or participating in (as a witness or otherwise)
any litigation, or investigation or proceeding by any third party or governmental agency or body, commenced or threatened, in each
case whether or not a party, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue
statement or omission, to the extent that any such expense is not paid under Sections 4.1(a) or 4.1(b) above;

 

    8 

     

    

 

provided, however, that the indemnity
provided pursuant to this Section 4.1 does not apply to the Buyer with respect to any loss, liability, claim, damage, action,
cost, judgment or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission
made in good faith reliance upon and in conformity with written information furnished to the Company by the Buyer expressly for
use in the Registration Statement (or any amendment thereto) or a Prospectus (or any amendment or supplement thereto), to the extent
incorporated therein.

 

4.2 Indemnification
by Buyer. The Buyer agrees to indemnify and hold harmless the Company, and each of its directors and officers (including each
director and officer of the Company who signed a Registration Statement), and each Person, if any, who controls the Company within
the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, solely with respect to information
provided by the Buyer referred to in the proviso to this Section 4.2, as follows:

 

(a)      against
any and all loss, liability, claim, damage, action, cost, judgment and expense whatsoever, as incurred, arising out of or based
upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment
thereto) pursuant to which the Registrable Securities of the Buyer were registered under the Securities Act, including all documents
incorporated therein by reference, or in any Prospectus (or any amendment or supplement thereto), including all documents incorporated
therein by reference, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading;

 

(b)      against
any and all loss, liability, claim, damage, judgment and expense whatsoever, as incurred, to the extent of the aggregate amount
paid in settlement of any litigation, or investigation or proceeding by any governmental agency or body, commenced or threatened,
or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission,
if such settlement is effected with the written consent of the Buyer; and

 

(c)      against
any and all expense whatsoever, as incurred (including reasonable fees and disbursements of counsel), reasonably incurred in investigating,
preparing, defending against or participating in (as a witness or otherwise) any litigation, or investigation or proceeding by
any governmental agency or body, commenced or threatened, in each case whether or not a party, or any claim whatsoever based upon
any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is
not paid under Sections 4.2(a) or 4.2(b) above;

 

provided, however, that the indemnity
provided pursuant to this Section 4.2 shall only apply with respect to any loss, liability, claim, damage, action, cost
judgment or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission made
in good faith reliance upon and in conformity with written information furnished to the Company by the Buyer expressly for use
in the Registration Statement (or any amendment thereto) or the Prospectus (or any amendment or supplement thereto), to the extent
incorporated therein. Notwithstanding the provisions of this Section 4.2, the Buyer and any permitted assignee shall not
be required to indemnify the Company, its officers, directors or control persons with respect to any amount in excess of the amount
of the total net proceeds to the Buyer or such permitted assignee, as the case may be, from sales of the Registrable Securities
of the Buyer under the Registration Statement or Prospectus, as applicable, that is the subject of the indemnification claim.

 

    9 

     

    

 

4.3 Conduct of Indemnification
Proceedings. An indemnified party hereunder shall give reasonably prompt notice to the indemnifying party of any action or
proceeding commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify the indemnifying
party (i) shall not relieve it from any liability which it may have under the indemnity agreement provided in Section 4.1
or 4.2 above, unless and only to the extent it did not otherwise learn of such action and the lack of notice by the indemnified
party results in the forfeiture by the indemnifying party of substantial rights and defenses, and (ii) shall not, in any event,
relieve the indemnifying party from any obligations to any indemnified party other than the indemnification obligation provided
under Section 4.1 or 4.2 above and the contribution obligation provided in Section 4.4 below. If the indemnifying
party so elects within a reasonable time after receipt of such notice, the indemnifying party may assume the defense of such action
or proceeding at such indemnifying party’s own expense with counsel chosen by the indemnifying party and approved by the
indemnified party, which approval shall not be unreasonably withheld; provided, however, that the indemnifying party will
not settle, compromise or consent to the entry of any judgment with respect to any such action or proceeding without the written
consent of the indemnified party unless such settlement, compromise or consent secures the unconditional release of the indemnified
party and does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any
indemnified party; and provided, further, that, if the indemnified party reasonably determines that a conflict of interest
exists where it is advisable for the indemnified party to be represented by separate counsel or that, upon advice of counsel, there
may be legal defenses available to it which are different from or in addition to those available to the indemnifying party (or
in the situation where the indemnifying party fails to take reasonable steps necessary to defend diligently the action or proceeding
within 20 Business Days after receiving notice from the indemnified party that the indemnified party believes the indemnifying
party has failed to do so), then the indemnifying party shall not be entitled to assume such defense and the indemnified party
shall be entitled to separate counsel at the indemnifying party’s expense, it being understood, however, that the indemnifying
party shall not, in connection with any one such action, claim or proceeding or separate but substantially similar or related actions,
claims or proceedings in the same jurisdiction arising out of the same general allegations or circumstances, be liable for the
reasonable fees and expenses of more than one additional firm of attorneys (together with appropriate local counsel) at any time
for all such indemnified parties. If the indemnifying party is not entitled to assume the defense of such action or proceeding
as a result of the second proviso to the preceding sentence, the indemnifying party’s counsel shall be entitled to conduct
the indemnifying party’s defense and counsel for the indemnified party shall be entitled to conduct the defense of the indemnified
party, it being understood that both such counsel will cooperate with each other to conduct the defense of such action or proceeding
as efficiently as possible. If the indemnifying party is not so entitled to assume the defense of such action or does not assume
such defense, the indemnifying party will not be liable for any settlement effected without the written consent of the indemnifying
party, not to be unreasonably withheld, delayed or conditioned. If an indemnifying party is entitled to assume, and assumes, the
defense of such action or proceeding in accordance with this paragraph, the indemnifying party shall not be liable for any fees
and expenses of counsel for the indemnified party incurred thereafter in connection with such action or proceeding.

 

    10 

     

    

 

4.4 Contribution.
In order to provide for just and equitable contribution in circumstances in which the indemnity agreement provided for in Sections
4.1 and 4.2 above is for any reason held to be unenforceable by a court of competent jurisdiction to any indemnified
party although applicable in accordance with its terms, the Company and the Buyer shall contribute to the aggregate losses, liabilities,
claims, damages, actions, costs, judgments and expenses of the nature contemplated by such indemnity agreement incurred by the
Company and the Buyer, in such proportion as is appropriate to reflect the relative fault of the Company on the one hand and the
Buyer on the other hand, in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages,
actions, costs, judgments or expenses. The relative fault of the indemnifying party and indemnified party shall be determined by
reference to, among other things, whether the action in question, including any untrue or alleged untrue statement of a material
fact or omission or alleged omission to state a material fact, relates to information supplied by the indemnifying party or the
indemnified party (and, with respect to Buyer, only written information expressly provided for use in the Registration Statement
(or any amendment thereto) or the Prospectus (or any amendment or supplement thereto), to the extent incorporated therein), and
the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action.

 

The parties hereto
agree that it would not be just or equitable if contribution pursuant to this Section 4.4 were determined by pro rata allocation
or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately
preceding paragraph. Notwithstanding the provisions of this Section 4.4, the Buyer shall not be required to contribute any
amount in excess of the amount that it would have been obligated to pay by way of indemnification if the indemnification provided
for under Section 4.2 had been available under the circumstances.

 

Notwithstanding the
foregoing, no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any indemnifying party who was not guilty of such fraudulent misrepresentation. For purposes
of this Section 4.4, each Person, if any, who controls the Buyer within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act, and any of their partners, members, officers, directors, employees, agents or representatives,
shall have the same rights to contribution as the Buyer, and each director of the Company, each officer of the Company who signed
a Registration Statement and each Person, if any, who controls the Company within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act shall have the same rights to contribution as the Company.

 

In addition, no Person
shall be obligated to contribute hereunder for any amounts in payment for any settlement of any action or claim, effected without
such Person’s written consent, which shall not be unreasonably withheld.

 

4.5 Survival. The indemnification
and contribution provisions in this Section 4 shall be a continuing right and shall survive the registration and sale of
any securities by any Person entitled to indemnification or contribution, as applicable hereunder, and the expiration or termination
of this Agreement.

 

    11 

     

    

 

Section 5. Registration Expenses

 

The Company shall pay
all expenses incident to the performance by the Company of its registration obligations under Sections 2 and 3 above,
including (i) all expenses incurred in connection with the preparation, printing and distribution of any Registration Statement
and Prospectus and all amendments and supplements thereto, (ii) SEC and state securities registration, listing and filing fees,
(iii) all fees and expenses of complying with securities or “blue sky” laws (including reasonable fees and disbursements
of counsel for the Buyer in connection with “blue sky” qualifications of the securities and determination of their
eligibility for investment under the laws of such jurisdictions), (iv) all FINRA fees and fees of any applicable stock exchange,
(v) fees and disbursements of counsel for the Company and fees and expenses for the independent certified public accountants retained
by the Company (including the expenses or costs associated with the delivery of any opinions or comfort letters), (vi) all internal
expenses of the Company (including all salaries and expenses of its officers and employees performing legal or accounting duties);
(vii) the fees and expenses of any Person, including special experts, retained by the Company in connection with the preparation
of any Registration Statement; and (viii) the fees and disbursements of counsel representing the Buyer registering Registrable
Securities pursuant to the Registration Statement and/or participating in the offering, as applicable. The Buyer shall be responsible
for the payment of any brokerage and sales commissions, fees and disbursements of the Buyer’s accountants and other advisors
(other than legal counsel to the Buyer), and any transfer taxes relating to the sale or disposition of the Registrable Securities
by the Buyer pursuant to this Agreement. The Company shall have no obligation to pay any other costs or expenses incurred by the
Buyer, including underwriting discounts or selling commissions attributable to the Registrable Securities being sold by the Buyer
thereof, which underwriting discounts or selling commissions shall be borne by the Buyer. In addition, in an underwritten offering,
all selling stockholders and the Company shall bear the expenses of the underwriters, pro rata, in proportion to the respective
amount of shares each sells in such offering.

 

Section 6. Rule 144 Compliance

 

The Company shall use
commercially reasonable efforts to file as and when applicable, on a timely basis, all reports required to be filed by it under
the Exchange Act. The Company shall use commercially reasonable efforts to make and keep current public information available as
specified in paragraph (c) of Rule 144 (or any successor rule) promulgated under the Securities Act. The Company shall use commercially
reasonable efforts to take such further action as may be reasonably required from time to time to enable the Buyer to Transfer
Registrable Securities without registration under the Securities Act within the limitation of the exemptions provided by Rule 144
or any other exemption from registration. Upon the request of the Buyer, the Company will deliver to the Buyer a written statement
as to whether it has complied with such requirements and, if not, the specifics thereof, as well as any such other information
as may be reasonably requested to allow the Buyer to sell its Registrable Securities pursuant to Rule 144. In connection with any
Transfer of Registrable Securities by the Buyer pursuant to Rule 144 promulgated under the Securities Act, the Company shall cooperate
with the Buyer to facilitate the timely preparation and delivery of certificates representing the Registrable Securities to be
sold and not bearing any Securities Act legend, and enable certificates for such Registrable Securities to be for such number of
shares and registered in such names as the Buyer may reasonably request at least five Business Days prior to any sale of Registrable
Securities hereunder or, if practicable, and at the request of the Buyer, have such Registrable Securities delivered electronically
via DWAC through the Depository Trust Company.

 

    12 

     

    

 

Section 7. Miscellaneous

 

7.1 Additional Agreements:
Certain Transactions.

 

(a)      In the event that any Common Shares or other Securities are issued in respect of, or in exchange for, or in substitution of the
Registrable Securities by reason of any reorganization, recapitalization, reclassification, merger, consolidation, spin-off, partial
or complete liquidation, share dividend, split-up, sale of assets, distribution to stockholders or combination of the shares or
any other similar change in the Company’s capital structure, the Company agrees that appropriate adjustments shall be made
to this Agreement to ensure that the Buyer has, immediately after consummation of such transaction, substantially the same rights
from the Company or another issuer of Securities, as applicable, as it has immediately prior to the consummation of such issuance
in respect of the Registrable Securities under this Agreement.

 

(b)      The Company shall not enter into any agreement with respect to the Company’s Securities that is inconsistent with the rights
granted to the Buyer under this Agreement, and no such agreement is currently in effect.

 

7.2 Entire Agreement.
This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter of this Agreement
and supersedes any and all prior agreements, negotiations, correspondence, undertakings, understandings and communications of the
parties hereto with respect to the subject matter of this Agreement.

 

7.3 Transaction
Costs. Except as otherwise provided herein, the parties to this Agreement will pay their own costs and expenses (including
legal, accounting and other fees) relating to this Agreement.

 

7.4 Modifications.
Any amendment or modification to this Agreement, including this undertaking itself, shall only be valid if effected by an instrument
or instruments in writing and shall be effective against each of the parties hereto that has signed such instrument or instruments.
The parties agree that they jointly negotiated and prepared this Agreement and that this Agreement will not be construed against
any party on the grounds that such party prepared or drafted the same.

 

7.5 Notices.
Notices will be deemed to have been received (a) upon receipt of a registered letter, (b) three Business Days following proper
deposit with an internationally recognized express overnight delivery service, or (c) in the case of transmission by email, as
of the date so transmitted (or if so transmitted after normal business hours at the place of the recipient, on the Business Day
following such transmission):

 

    13 

     

    

 

If to the Company:

 

Avenue Therapeutics, Inc.

2 Gansevoort Street, 9th Floor

New York, NY 10014

Attn: Dr. Lucy Lu, M.D.

Email: llu@avenuetx.com

 

With a copy (which shall not constitute notice) to:

 

Alston & Bird LLP

90 Park Avenue, 12th Floor

New York, NY 10016

Attn: Mark McElreath

Email: mark.mcelreath@alston.com

 

If to Buyer:

 

InvaGen Pharmaceuticals Inc.

Site B, 7 Oser Ave.

Hauppauge, NY 11788c/o

A.S. Kumar, Esq.

Global General Counsel

Cipla Ltd.

Cipla House, Peninsula Business Park,

Ganapatrao Kadam Marg, Lower Parel West,

Mumbai, Maharashtra 400013, India

Email: as.kumar@cipla.com and cosecretary@cipla.com

 

With a copy (which shall not constitute notice) to:

 

InvaGen Pharmaceuticals Inc.

Site B, 7 Oser Ave.

Hauppauge, NY 11788

c/o

Nishant Saxena

Global Chief Strategy Officer

Cipla Ltd.

Cipla House, Peninsula Business Park,

Ganapatrao Kadam Marg, Lower Parel West,

Mumbai, Maharashtra 400013, India

Email: nishant.saxena@cipla.com

 

With a copy (which shall not constitute notice) to:

 

Hughes Hubbard & Reed LLP

One Battery Park Plaza

New York, NY 10004-1482

Attn: Kenneth A. Lefkowitz

Email: ken.lefkowitz@hugheshubbard.com

 

or to such other address as may be hereafter
communicated in writing by the parties in a notice given in accordance with this Section 7.5, which address shall then apply
to the respective notice provisions of the SPMA and all other Ancillary Agreements.

 

7.6 Public Announcements.
Except as required by Legal Requirements or by the requirements of any stock exchange on which the securities of a party hereto
or any of its Affiliates are listed, no party to this Agreement will make, or cause to be made, any press release or public announcement
in respect of this Agreement or the transactions contemplated hereby or otherwise communicate with any news media with respect
to the foregoing without prior notification to the other parties, and the parties to this Agreement will consult with each other
and cooperate as to the form, timing and contents of any such press release, public announcement or disclosure.

 

    14 

     

    

 

7.7 Severability.
Each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable Legal Requirements,
but if any provision of this Agreement is found to be unenforceable or invalid under applicable Legal Requirements, such provision
will be ineffective only to the extent of such unenforceability or invalidity, and the parties will negotiate in good faith to
modify this Agreement so that the unenforceable or invalid provision is replaced by such valid and enforceable provision which
the parties consider, in good faith, to match as closely as possible the invalid or unenforceable provision and to achieve the
same or a similar economic effect and to give effect to the parties’ original intent. The remaining provisions of this Agreement
will continue to be binding and in full force and effect.

 

7.8 Assignment.
No party hereto may assign, in whole or in part, or delegate all or any part of its rights, interests or obligations under this
Agreement without the prior written consent of the other party. Any assignment or delegation made without such consent will be
void. Notwithstanding the foregoing, Buyer shall be entitled to (a) assign its rights under this Agreement to any one of its Affiliates,
and (b) assign any or all of its rights and obligations under this Agreement (in whole or in part) as collateral security in a
financing transaction.

 

7.9 Governing Law.
This Agreement and any claims or causes of action pursuant to it will be governed by and construed in accordance with the laws
of the State of Delaware, without regard for its principles of conflict of laws.

 

7.10 Specific Performance.
Each party acknowledges and agrees that the other party would be irreparably damaged if the provisions of this Agreement are not
performed in accordance with their terms and that any breach of this Agreement and the non-consummation of the transactions contemplated
hereby by either party could not be adequately compensated in all cases by monetary damages alone. Accordingly, in addition to
any remedy to which such other party may be entitled under Section 7.11, provisional measures and injunctive relief necessary
to protect the possibility of each party to seek specific performance from the other from the tribunal referred to in Section
7.11 can be sought from any court of competent jurisdiction. Each of the parties hereto (i) agrees that it shall not oppose
the granting of any such relief and (ii) hereby irrevocably waives any requirement for the security or posting of any bond in connection
with any such relief (it is understood that clause (i) of this sentence is not intended to, and shall not, preclude any party hereto
from litigating on the merits the substantive claim to which such remedy relates).

 

    15 

     

    

 

7.11 Submission
to Jurisdiction. Each of the parties hereto irrevocably agrees that any Proceeding with respect to this Agreement and the rights
and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Agreement and the rights
and obligations arising hereunder brought by any other party hereto or its successors or assigns shall be brought and determined
exclusively in the Court of Chancery of the State of Delaware, or in the event (but only in the event) that such court does not
have subject matter jurisdiction over such action or proceeding, in the federal courts sitting in the State of Delaware. Each of
the parties hereto agrees that mailing of process or other papers in connection with any such action or proceeding in the manner
provided in Section 7.5 or in such other manner as may be permitted by applicable Legal Requirements, will be valid and
sufficient service thereof. Each of the parties hereto hereby irrevocably submits with regard to any such action or proceeding
for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid courts
and agrees that it will not bring any action relating to this Agreement or any of the transactions contemplated by this Agreement
in any court or tribunal other than the aforesaid courts. Each of the parties hereto hereby irrevocably waives, and agrees not
to assert, by way of motion, as a defense, counterclaim, or otherwise, in any action or proceeding with respect to this Agreement
and the rights and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Agreement
and the rights and obligations arising hereunder: (a) any claim that it is not personally subject to the jurisdiction of the above
named courts for any reason other than the failure to serve process in accordance with this Section 7.11; (b) any claim
that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts
(whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment
or otherwise); and (c) to the fullest extent permitted by the applicable Legal Requirements, any claim that (i) the suit, action
or proceeding in such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper,
or (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.

 

7.12 Waiver of Jury
Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO
INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY
HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT or
the transactions contemplated hereby. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT: (A) NO REPRESENTATIVE
OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER
IN THE EVENT OF A LEGAL ACTION; (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER; (C) SUCH PARTY MAKES THIS WAIVER
VOLUNTARILY; AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS SECTION 7.12.

 

7.13 Waiver.
Any term or condition of this Agreement may be waived at any time by the party that is entitled to the benefit thereof, but no
such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such
term or condition, and no waiver by any party of any default, misrepresentation, or breach of warranty or covenant hereunder, shall
be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty, covenant or agreement hereunder
or affect in any way any rights arising by virtue of any such prior or subsequent occurrence. No failure or delay of any party
in exercising any right or remedy hereunder shall operate as a waiver thereof, and no waiver by any party of any term or condition
of this Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of the same or any other term or
condition of this Agreement on any future occasion.

 

7.14 Counterparts;
Facsimile Signature. This Agreement may be executed in one (1) or more counterparts, by original or facsimile (or other such
electronically transmitted) signature, each of which will be deemed an original, but all of which will constitute one and the same
instrument. Any party executing this Agreement by facsimile (or other such electronically transmitted) signature shall, upon request
from another party hereto, promptly deliver to the requesting party an original counterpart of such signature.

 

    16 

     

    

 

7.15 Rights Cumulative.
All rights and remedies of each of the parties under this Agreement will be cumulative, and the exercise of one or more rights
or remedies will not preclude the exercise of any other right or remedy available under this Agreement or applicable Legal Requirements.

 

7.16 Interpretation.
(a) The words “hereof”, “herein”, and “hereunder” and words of similar import, when used in
this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement; (b) the words
“date hereof,” when used in this Agreement, shall refer to the date set forth in the Preamble; (c) the terms defined
in the singular have a comparable meaning when used in the plural, and vice versa; (d) the terms defined in the present tense
have a comparable meaning when used in the past tense, and vice versa; (e) any references herein to a specific Section or
Article shall refer, respectively, to Sections or Articles of this Agreement; (f) wherever the word “include”,
“includes”, or “including” is used in this Agreement, it shall be deemed to be followed by the words “without
limitation”; (g) references herein to any gender includes each other gender; (h) the word “or” shall
not be exclusive; (i) the headings herein are for convenience of reference only, do not constitute part of this Agreement
and shall not be deemed to limit or otherwise affect any of the provisions hereof; (j) any references herein to any Governmental
Authority shall be deemed to also be a reference to any successor Governmental Authority thereto; and (k) the parties hereto
have participated jointly in the negotiation and drafting of this Agreement and, in the event that an ambiguity or question of
intent or interpretation arises, this Agreement shall be construed as jointly drafted by the parties hereto and no presumption
or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.

 

7.17 Survival.
This Section 7 shall survive any termination of this Agreement.

 

[Signature Page Follows]

 

    17 

     

    

 

IN WITNESS WHEREOF,
each of the parties hereto has caused this Agreement to be duly executed on its behalf as of the date first herein above set forth.

 

	 	COMPANY:
	 	 
	 	AVENUE THERAPEUTICS, INC.
	 	 
	 	By:	/s/ Lucy Lu, M.D.
	 	 
	 	Name: Lucy Lu, M.D. 
	 	 
	 	Title: President & CEO  
	 	 
	 	BUYER:
	 	 
	 	INVAGEN PHARMACEUTICALS INC.
	 	 
	 	By: 	/s/ Nikhil Lalwani
	 	 
	 	Name: Nikhil Lalwani 
	 	 
	 	Title: CEO

 

[Signature Page to Registration Rights
Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]